Significantly higher risk seen for rheumatoid arthritis and psoriasis
THURSDAY, Jan. 23, 2025 (HealthDay News) — On a global scale, childhood maltreatment is associated with a higher risk for developing some immune-mediated inflammatory disorders (IMIDs), according to a study published online Nov. 30 in Heliyon.
Liam Snook, from the University of Birmingham in the United Kingdom, and colleagues investigated the association between childhood maltreatment and IMIDs. The analysis included 256,130 exposed patients and 712,478 matched, unexposed patients identified from a U.K. primary care database (Jan. 1, 1995, to Jan. 31, 2021).
The researchers found that individuals exposed to childhood maltreatment had a significantly increased risk for developing rheumatoid arthritis (adjusted hazard ratio [aHR], 1.39) and psoriasis (aHR, 1.16). However, there was no statistically significant association with the risk for developing inflammatory bowel disease, multiple sclerosis, or systemic lupus erythematosus. Exposed individuals had a lower risk for celiac disease (aHR, 0.74) versus the unexposed group.
“Childhood maltreatment is estimated to affect one in three children globally; therefore, an increased risk of developing rheumatoid arthritis and psoriasis represents a substantial contribution to the burden of IMIDs,” the authors write. “Implementation of broad public health approaches to prevent and detect childhood maltreatment and its negative downstream consequences, such as IMID development, is essential.”
Virtual Reality-Based Digital Defocus Vision Training May Aid Myopia in Children
Therapist-Led Online Cognitive Behavioral Therapy Aids Depression
Extreme Heat Linked to 33 Clinically Reportable Diagnoses
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Probable Postictal Psychosis Linked to Risk for Subsequent Primary Psychotic Disorders
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing
Childhood-Onset Epilepsy Tied to Lower Rate of Educational Attainment
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings